Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

Clin Epigenetics. 2018 May 29;10:70. doi: 10.1186/s13148-018-0503-2. eCollection 2018.

Abstract

We have previously shown that aberrant promoter methylation of ZNF331 is a potential biomarker for colorectal cancer detection with high sensitivity (71%) and specificity (98%). This finding was recently confirmed by others, and it was additionally suggested that promoter methylation of ZNF331 was an independent prognostic biomarker for colorectal cancer (n = 146). In the current study, our initial colorectal cancer sample series was extended to include a total of 423 cancer tissue samples. Aberrant promoter methylation was found in 71% of the samples, thus repeatedly suggesting the biomarker potential of ZNF331 for detection of colorectal cancer. Furthermore, multivariate Cox's analysis indicated a trend towards inferior overall survival for colorectal cancer patients with aberrant methylation of ZNF331.

Keywords: Colorectal cancer; DNA methylation; Diagnosis; Prognosis; ZNF331.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics*
  • Cell Line, Tumor
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / genetics
  • DNA Methylation*
  • DNA-Binding Proteins / genetics*
  • Epigenesis, Genetic
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Proteins / genetics*
  • Prognosis
  • Promoter Regions, Genetic
  • Sensitivity and Specificity
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Neoplasm Proteins
  • ZNF331 protein, human